Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 2.15 -4.66% -0.11
CKPT closed down 4.66 percent on Monday, December 10, 2018, on 37 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CKPT trend table...

Date Alert Name Type % Chg
Dec 10 Narrow Range Bar Range Contraction 0.00%
Dec 10 NR7 Range Contraction 0.00%
Dec 10 NR7-2 Range Contraction 0.00%
Dec 10 Down 3 Days in a Row Weakness 0.00%
Dec 10 Down 4 Days in a Row Weakness 0.00%
Dec 10 Down 5 Days in a Row Weakness 0.00%
Dec 7 20 DMA Resistance Bearish -4.66%
Dec 7 NR7 Range Contraction -4.66%
Dec 7 Inside Day Range Contraction -4.66%
Dec 7 Down 3 Days in a Row Weakness -4.66%

Older signals for CKPT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Is CKPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.29
52 Week Low 1.89
Average Volume 48,947
200-Day Moving Average 3.3875
50-Day Moving Average 2.5586
20-Day Moving Average 2.296
10-Day Moving Average 2.304
Average True Range 0.2969
ADX 14.17
+DI 20.9513
-DI 20.5036
Chandelier Exit (Long, 3 ATRs ) 1.9993
Chandelier Exit (Short, 3 ATRs ) 2.7807
Upper Bollinger Band 2.5567
Lower Bollinger Band 2.0353
Percent B (%b) 0.22
BandWidth 22.709059
MACD Line -0.0761
MACD Signal Line -0.0965
MACD Histogram 0.0204
Fundamentals Value
Market Cap 54.54 Million
Num Shares 25.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -1.95
Price-to-Sales 75.20
Price-to-Book 6.30
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.30
Resistance 3 (R3) 2.31 2.26 2.28
Resistance 2 (R2) 2.26 2.23 2.26 2.27
Resistance 1 (R1) 2.21 2.20 2.19 2.20 2.26
Pivot Point 2.16 2.16 2.15 2.16 2.16
Support 1 (S1) 2.11 2.13 2.09 2.10 2.04
Support 2 (S2) 2.06 2.10 2.06 2.03
Support 3 (S3) 2.01 2.06 2.03
Support 4 (S4) 2.00